InMed Pharmaceuticals (INM) Gross Margin (2021 - 2025)

InMed Pharmaceuticals' Gross Margin history runs 5 years deep, the most recent figure standing at 22.46% for Q4 2025.

• On a quarterly basis, Gross Margin fell 1900.0% year-over-year to 22.46% in Q4 2025; TTM through Dec 2025 was 29.73%, a 566.0% decrease from a year earlier, with the FY2025 full-year figure at 34.53%, up 1058.0% from the prior year.
• Gross Margin declined to 22.46% in Q4 2025 per INM's latest filing, from 35.99% in the prior quarter.
• Across five years, Gross Margin topped out at 67.95% in Q2 2023 and bottomed at 153.07% in Q3 2022.
• The 5-year median for Gross Margin is 30.38% (2022), against an average of 21.7%.
• Across the five-year window, Gross Margin soared 15542 bps in 2023 and sank 3163 bps in 2024, its largest moves.
• Year by year, Gross Margin stood at 42.08% in 2021, then plunged by 34 bps to 27.92% in 2022, then slipped by 6 bps to 26.14% in 2023, then soared by 59 bps to 41.46% in 2024, then plunged by 46 bps to 22.46% in 2025.
• Per Business Quant, the three latest INM Gross Margin figures stand at 22.46% (Q4 2025), 35.99% (Q3 2025), and 44.2% (Q2 2025).